Abstract:
Triple negative breast cancer (TNBC) has a more aggressive clinical course
compared to other breast cancer subtypes. The presence of a triple negative
receptor status causes the ineffectiveness of such types of targeted treatment as
hormonal therapy and targeted therapy with Herceptin , in contrast to luminal
and Her-2/ neu -positive tumors. In this regard, chemotherapy today remains the
only accepted method of systemic treatment in this category of patients. Over the
past few years, great advances have been made in the comprehensive treatment
of TNBC. But, despite this, TN breast cancer remains one of the aggressive forms
of malignant breast tumors with a high level of metastasis and low survival
compared to other subtypes of breast cancer
